_MACHINE TRANSLATION_
The Management Board of Bioceltix S.A. with its registered office in Wrocław (the “Issuer” or the “Company”), with reference to ESPI Current Report No. 16/2025 dated 16 July 2025 concerning the execution of a grant agreement for the project entitled “Construction and Launch of a Pharmaceutical Manufacturing Facility for Innovative Advanced Therapy Veterinary Medicinal Products” (the “Project”), and ESPI Current Report No. 29/2026 dated 23 July 2026 concerning the finality of the building permit decision for the project entitled “Manufacturing Facility for Biological Veterinary Medicinal Products” (the “Investment”), hereby informs that on 4 August 2026 it entered into an agreement (the “Agreement”) with Intero sp. z o.o., with its registered office in Wrocław (the “Contractor”).
The Agreement was concluded following a procurement procedure conducted in accordance with the principle of competitiveness and is intended to support the implementation of the Project co-financed by the European Union under the European Funds for a Modern Economy programme.
The subject matter of the Agreement is the performance of construction works comprising the steel structure of internal and external mezzanines together with the equipment provided for in the design documentation of the veterinary medicinal products manufacturing facility located at 1 Skrzypowa Street, Wrocław.
The scope of the Contractor’s works includes, in particular:
- construction of the steel structure of the internal and external mezzanines;
- construction of foundations for the steel structure;
- construction of foundation slabs for storage tanks, a CO₂ cylinder bundle and a power generator;
- execution of the necessary demolition and restoration works, including, among others, the restoration of parts of the parking area and warehouse flooring;
- preparation of workshop documentation for all steel structure components, including supports and fixings for grating platforms and handrails.
The Contractor has undertaken to complete the works within 14 weeks from the date on which the Issuer hands over the construction site. A detailed implementation schedule will be delivered to the Issuer prior to the commencement of works.
The Contractor’s total lump-sum remuneration under the Agreement amounts to PLN 1,995,662.60 net, plus applicable VAT.
In accordance with the payment schedule, 30% of the total remuneration will be paid as an advance payment, while the remaining 70% will be paid upon proper completion of the works and final acceptance without reservations. Payment of the advance is conditional upon the Contractor first providing a bank or insurance guarantee securing the repayment of 100% of the gross advance amount.
The Contractor has granted the Issuer a quality warranty for the completed works for a period of 120 months from the date of final acceptance. The Contractor’s liability period under the statutory warranty for defects is equal to the warranty period.
The Agreement further provides for the establishment by the Contractor of a performance security equal to 10% of the net remuneration. In addition, the Agreement contains provisions relating, in particular, to the acceptance of works, rectification of defects and deficiencies, the Contractor’s liability, contractual penalties, confidentiality, protection of inside information within the meaning of the MAR Regulation, transfer of intellectual property rights, use of subcontractors, amendments to the Agreement and its termination. The remaining provisions of the Agreement do not materially differ from standard terms commonly applied in agreements concerning this type of construction work.
The execution of the Agreement constitutes another significant stage in the implementation of the Investment and follows the Issuer’s obtaining a final building permit decision. The construction of the steel structure and infrastructure covered by the Agreement is necessary for the continuation of the works related to the construction and commissioning of the new pharmaceutical manufacturing facility.
The Management Board of the Issuer considers the execution of the Agreement to be material due to its value and the importance of its subject matter for the Investment implementation timetable, the achievement of the Company’s strategic objectives and its future operational and financial position.
Attachments: None
Signatures of persons representing the Company:
Łukasz Bzdzion – President of the Management Board
Paweł Wielgus – Member of the Management Board